Top

Published in:

01-08-2020 | Chronic Lymphocytic Leukemia | Original Article

Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia

Authors: Salah Aref, Alshaimaa Mohamed, Heba El Shehawy, Emaad Azmy

Published in: Comparative Clinical Pathology | Issue 4/2020

Abstract

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among western population. Many interesting reports suggest the role of IL-10 polymorphisms in CLL oncogenesis. This study aimed to study the relation between IL-10 (rs1800896)-1082 (G/A) gene polymorphism and the risk of development of B cell chronic lymphocytic leukemia and its impact on the patient outcome. IL-10 (rs1800896)-1082 (G/A) gene polymorphism was assessed in fifty patients with chronic lymphocytic leukemia as well as 50 age and sex-matched apparently healthy controls using polymerase chain reaction (PCR). The IL-10 (rs1800896) AG hetero, GG homo, AG + GG genotypes, and G allele showed significantly higher frequency (P > 0.001) in CLL cases when compared to control groups. The genotype AG + GG were significantly associated with advanced stages (P > 0.001), short time to first treatment (TFT) (P = 0.032), shorter progression free survival (PFS) (P = 0.044), and lower response to treatment (P = 0.003) as compared to wild genotype (AA wild). The IL-10 (rs1800896) genotypes (GG, AG) might have a role in the pathogenesis of CLL and have deleterious impact on the CLL patient’s outcome.

Author (2016) An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17(6):779–790CrossRef

Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G (2005) The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105(12):4894–4895CrossRef

Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82(7):2169–2174CrossRef

Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson J, Axelson H, Castaños-Velez E, Lungren H, Waal Malefyt R, Harris H, Ziche M, Teresa BM (2000) Abolished antigenicity and tumorigenicity of Burkitt lymphoma by interleukin- 10. Blood 96:2568–2573CrossRef

Domingo-Domènech E, Benavente Y, González-Barca E, Montalban C, Gumà J, Bosch R, Rothman N (2007) Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 92(11):1475–1481CrossRef

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C (2015) Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl_5):78–v84CrossRef

Groux H, Bigler M, de Vries JE, Roncarolo MG (1998) Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 60:3188–3193

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) guidelines. Blood 111(12):5446–5456CrossRef

Hamblin TJ (2009) Just exactly how common is CLL? Leuk Res 33(11):1452–1453CrossRef

Hartmann C, Lennartz K, Ibrahim H, Coz A, Kasper Y, Lenz C, & Polidori M (2016) Stable 16-year storage of DNA purified with the QIAamp® DNA Blood Mini Kit. Application note QIAGEN GmbH, QIAGEN Straße 1, Hilden, Germany

Herishanu Y, Katz BZ, Lipsky A, Wiestner A (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin 27(2):173–206CrossRef

Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Salles G (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103(9):3529–3534CrossRef

Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, Cebula-Obrzut B, Robak T (2013) Polymorphisms of TNF and IL- 10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosom Cancer 52(3):287–296CrossRef

Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178(5):2623–2629CrossRef

Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109CrossRef

Ovsepyan VA, Gabdulkhakova AK, Shubenkiva AA, Zotina EN (2015) Role of interleukin-10 gene promoter region polymorphism in the development of chronic lymphoid leukemia. Bull Exp Biol Med 160(2):275–277CrossRef

Rahman HAA, Khorshied MM, Khorshid OMR, Mourad HM (2018) Association of Interleukin-2-330T/G and Interleukin-10-1082A/G genetic polymorphisms with B-cell non-Hodgkin lymphoma in a cohort of Egyptians. Turkish J Hematol 35(2):99–108CrossRef

Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219–234CrossRef

Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21(5):331–344CrossRef

Sami RM, Nasr AS, Ibrahim NY, Darweesh DO, El Hussieny NM (2012) Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survival. Comp Clin Pathol 21(6):1407–1415CrossRef

Schoof N, Franklin J, Fürst R, Zander T, Von Bonin F, Peyrade F, Re D (2013) Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. Oncologist 18(1):80–89CrossRef

Stickel J, Kowalewski D, Rammensee HG, Stevanovic S (2018) Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL). U.S. Patent Application No.; 10/000,533

Trinchieri G (2007) Interleukin-10 production by effector T cells: Th1 cells show self-control. J Exp Med 204(2):239–243CrossRef

Title: Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia
Authors: Salah Aref
Alshaimaa Mohamed
Heba El Shehawy
Emaad Azmy
Publication date: 01-08-2020
Publisher: Springer London
Keyword: Chronic Lymphocytic Leukemia
Published in: Comparative Clinical Pathology / Issue 4/2020
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-020-03139-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Effect of oral melatonin administration on inflammatory cytokines and acute phase proteins after the castration of dogs

Hepatocurative effect of aqueous extract of Scoparia dulcis (sweet broom) root on carbon tetrachloride-induced hepatotoxicity in albino rats

Ameliorative effect of Gongronema latifolium leaf extract on alloxan-induced diabetic cardiomyopathy in Wistar rats model

Pathological and molecular detection of a rare case of cutaneous cryptococcosis in a 9-year-old horse

Protective and therapeutic effects of Phoenix dactylifera leaf extract on pancreatic β-cells and diabetic parameters in streptozotocin-induced diabetic rats

Pathology and molecular diagnosis of canine parvoviral enteritis in Nigeria: case report